Similar articles

• Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?

  Segel GB, Simon W, Lichtman MA. Segel GB, et al. Pediatr Blood Cancer. 2011 Jul 15;57(1):8-9. doi: 10.1002/pbc.23128. Epub 2011 Apr 7. Pediatr Blood Cancer. 2011. PMID: 21480473 No abstract available.
• Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease.

  Noguchi CT, Dover GJ, Rodgers GP, Serjeant GR, Antonarakis SE, Anagnou NP, Higgs DR, Weatherall DJ, Schechter AN. Noguchi CT, et al. J Clin Invest. 1985 May;75(5):1632-7. doi: 10.1172/JCI111870. J Clin Invest. 1985. PMID: 2581999 Free PMC article.
• Red cell membrane abnormalities in sickle cell anemia.

  Bookchin RM, Lew VL. Bookchin RM, et al. Prog Hematol. 1983;13:1-23. Prog Hematol. 1983. PMID: 6322226 Review. No abstract available.
• [Treatment of thalassemia and sickle cell anemia in children].

  Girot R. Girot R. Ann Pediatr (Paris). 1978 May-Jun;25(5-6):277-84. Ann Pediatr (Paris). 1978. PMID: 16114336 Review. French. No abstract available.
• Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.

  Fertrin KY, Costa FF. Fertrin KY, et al. Expert Rev Hematol. 2010 Aug;3(4):443-58. doi: 10.1586/ehm.10.44. Expert Rev Hematol. 2010. PMID: 21083035 Review.